Mental Health Care Provider's Perspectives Toward Adopting a Novel Technology to Improve Medication Adherence.


Journal

Psychiatric research and clinical practice
ISSN: 2575-5609
Titre abrégé: Psychiatr Res Clin Pract
Pays: United States
ID NLM: 101776485

Informations de publication

Date de publication:
2022
Historique:
received: 20 07 2021
revised: 28 01 2022
accepted: 12 02 2022
entrez: 18 10 2022
pubmed: 19 10 2022
medline: 19 10 2022
Statut: epublish

Résumé

To understand perspectives of mental health care providers regarding barriers and drivers of adopting a medication ingestible event monitoring (IEM) system in clinical practice. Between April and October 2019, a cross-sectional, online survey was conducted among 131 prescribing clinicians and 119 non-prescribing clinicians providing care to patients with major depressive disorder, bipolar disorder, and schizophrenia. Most prescribing clinicians were physicians (79.4%) while most non-prescribing clinicians (52.9%) were licensed clinical social workers, followed by counselors (30.8%), clinical psychologists (13.4%), and case managers (2.5%). Most respondents (93.2%) reported that clinicians can influence adherence, that the IEM technology was in their patients' best interest (63.6%), and a willingness to beta test the technology (54.8%). Support was positively associated with prescribing clinicians (OR: 2.2; 95% CI: 1.1, 4.5), belief that antipsychotics reduce the health, social, or financial consequences of the condition (OR: 3.8; 95% CI: 1.3, 11.0), concern for patients' well-being without monitoring (OR: 3.3; 95% CI: 1.2, 8.7), and belief the technology will enhance clinical alliance (OR: 3.1; 95% CI: 1.5, 6.3) or improve patient engagement (OR: 3.0; 95% CI: 1.5, 6.2). Support was inversely related to concerns about appropriate follow-up actions (OR: 0.4; 95% CI: 0.2, 0.9) and responsibilities (OR: 0.3; 95% CI: 0.1, 0.8) when using the technology. Our results suggest that IEM sensor technology adoption will depend upon additional evidence that patients will actively engage in the use of the technology, will benefit from the technology through improved outcomes, and that the additional burden placed upon providers is minimal compared to the potential benefit.

Identifiants

pubmed: 36254189
doi: 10.1176/appi.prcp.20210021
pii: RCP21043
pmc: PMC9558921
doi:

Types de publication

Journal Article

Langues

eng

Pagination

61-70

Informations de copyright

© 2022 Otsuka Pharmaceutical Development & Commercialization, Inc. Psychiatric Research and Clinical Practice published by Wiley Periodicals LLC on behalf of American Psychiatric Association.

Références

Perspect Health Inf Manag. 2016 Jan 01;13:1d
pubmed: 26903782
Int J Clin Pract. 2012 Jun;66(6):565-73
pubmed: 22574724
J Manag Care Spec Pharm. 2016 Nov;22(11):1349-1361
pubmed: 27783548
Neuron. 2000 Nov;28(2):335-41
pubmed: 11144343
Arch Intern Med. 2000 Jul 24;160(14):2101-7
pubmed: 10904452
J Psychosom Res. 2010 Dec;69(6):591-9
pubmed: 21109048
Ann Fam Med. 2016 Sep;14(5):415-21
pubmed: 27621157
Int J Bipolar Disord. 2017 Dec;5(1):6
pubmed: 28155206
Prim Care Companion J Clin Psychiatry. 2009;11(4):147-54
pubmed: 19750066
Neuropsychiatr Dis Treat. 2017 Oct 19;13:2641-2651
pubmed: 29089771
Expert Opin Drug Saf. 2018 Sep;17(9):849-852
pubmed: 30073875
J Gen Intern Med. 2017 Jan;32(1):93-100
pubmed: 27599489
Psychopharmacol Bull. 1997;33(1):87-91
pubmed: 9133756
Am Fam Physician. 2000 Sep 15;62(6):1343-53, 1357-8
pubmed: 11011863
Neuropsychiatr Dis Treat. 2016 Oct 11;12:2587-2594
pubmed: 27785036
Bipolar Disord. 2006 Jun;8(3):232-41
pubmed: 16696824
JAMA. 2003 Nov 12;290(18):2443-54
pubmed: 14612481
Curr Opin Psychiatry. 2013 Sep;26(5):446-52
pubmed: 23880592
PLoS One. 2013;8(1):e53373
pubmed: 23308203
J Manag Care Spec Pharm. 2016 Nov;22(11):1285-1291
pubmed: 27783545
Syst Rev. 2020 Jan 16;9(1):17
pubmed: 31948489
Neuropsychiatr Dis Treat. 2018 Feb 16;14:553-565
pubmed: 29497299
Clinicoecon Outcomes Res. 2018 Oct 02;10:573-585
pubmed: 30323635
J Med Internet Res. 2018 Dec 13;20(12):e11254
pubmed: 30545807
Res Social Adm Pharm. 2016 Mar-Apr;12(2):218-46
pubmed: 26164400
Cochrane Database Syst Rev. 2018 Jan 10;1:CD012042
pubmed: 29320600
BMJ Open. 2018 Jan 23;8(1):e015332
pubmed: 29362241
Psychiatry Clin Neurosci. 2005 Aug;59(4):403-9
pubmed: 16048445
Curr Med Res Opin. 2010 Apr;26(4):777-85
pubmed: 20095797
PLoS One. 2019 Mar 12;14(3):e0213432
pubmed: 30861014
BMC Med Res Methodol. 2011 Nov 03;11:149
pubmed: 22050830
J Clin Psychiatry. 2016 Sep;77(9):e1101-e1107
pubmed: 27487251
Neuropsychiatr Dis Treat. 2015 Apr 16;11:1077-90
pubmed: 25931823
J Clin Psychiatry. 2018 May/Jun;79(3):
pubmed: 29873960
Br J Psychiatry. 1987 Mar;150:285-92
pubmed: 3311267
Int J Clin Pract. 2011 Sep;65(9):954-75
pubmed: 21849010
Transl Behav Med. 2015 Dec;5(4):470-82
pubmed: 26622919
Am J Psychiatry. 2004 Apr;161(4):692-9
pubmed: 15056516
J Clin Psychopharmacol. 2016 Aug;36(4):355-71
pubmed: 27307187
Patient Prefer Adherence. 2017 Jun 27;11:1071-1081
pubmed: 28721020
Patient Relat Outcome Meas. 2014 Jun 23;5:43-62
pubmed: 25061342
Psychiatr Serv. 2007 Sep;58(9):1187-92
pubmed: 17766564

Auteurs

Joshua N Liberman (JN)

Health Analytics LLC Columbia Maryland USA.

Tigwa Davis (T)

Health Analytics LLC Columbia Maryland USA.

Dawn Velligan (D)

University of Texas Health Science Center San Antonio Texas USA.

Delbert Robinson (D)

Northwell Health Feinstein Institutes for Medical Research Hempstead New York USA.

William Carpenter (W)

University of Maryland School of Medicine Baltimore Maryland USA.

Chris Jaeger (C)

JHC Solutions LLC San Francisco California USA.

Heidi Waters (H)

Otsuka Pharmaceutical Development & Commercialization Inc Princeton New Jersey USA.

Charles Ruetsch (C)

Health Analytics LLC Columbia Maryland USA.

Felicia Forma (F)

Otsuka Pharmaceutical Development & Commercialization Inc Princeton New Jersey USA.

Classifications MeSH